Using a digital tool to monitor symptoms in head and neck cancer patients
Official title: Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations
Run by The University of Texas Health Science Center, Houston · NCT06030011 · Data updated 2026-11-12
This study tests if a new digital tool that helps head and neck cancer patients report their symptoms during radiation therapy can improve their swallowing, taste, smell, and social life compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 270 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 5 sites (Kansas City, Kansas and 4 other locations) |
| Status | Recruiting |
| Started | June 25, 2024 |
| Main results expected | August 31, 2028 |
| Study ends | August 31, 2028 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT06030011 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with histologically diagnosed head and neck cancer who are undergoing curative radiation therapy and can communicate in English or Spanish.
✕Probably not a fit
Patients with medical conditions that impair their ability to provide informed consent or complete questionnaires may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of the New York University Electronic Patient Visit Assessment (ePVA), a digital system designed for real-time monitoring of symptoms in patients with head and neck cancer undergoing radiation therapy. The ePVA allows patients to report their symptoms, enabling clinicians to provide timely interventions. The study aims to compare outcomes between patients using the ePVA and those receiving usual care, focusing on improvements in swallowing, taste, smell, and social function four weeks post-treatment. It also seeks to identify strategies for implementing the ePVA effectively in both rural and urban healthcare settings.
Why it matters
Potential benefit: If successful, this approach could lead to improved symptom management and quality of life for head and neck cancer patients during and after treatment.
How similar studies have gone: Other studies have shown promise in using digital patient-reported outcomes for symptom management, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (Patient Participants): * Individuals with histologically diagnosed head and neck cancer (HNC) undergoing curative radiation therapy with or without chemotherapy * English or Spanish speaking Inclusion Criteria (Clinician Participants): * Clinicians (i.e., physicians, nurses, dentists, physician assistants, social workers, nutritionists, speech swallow therapists) caring for patients with head and neck cancer at the participating institutions Exclusion Criteria (Patient and Clinician Participants): * Any medical condition that could limit the participant's ability to provide informed consent and complete the questionnaires.
Where it's running
-
University of Kansas Cancer Center
Kansas City, Kansas, United States Recruiting -
NYU Langone Perlmutter Cancer Center
New York, New York, United States Recruiting -
NYU Meyers College of Nursing
New York, New York, United States Not yet recruiting -
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States Not yet recruiting -
UTHealth Houston Cizik School of Nursing
Houston, Texas, United States Not yet recruiting
Study contacts
- Principal investigator: Janet H. Van Cleave, PhD, RN — The University of Texas Health Science Center at Houston (UTHealth Houston)
- Study coordinator: Janet H. Van Cleave, PhD, RN
- Email: Janet.H.VanCleave@uth.tmc.edu
- Phone: (713) 500-2000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.